NR4A1 Exerts Pro‐Tumor Role in Glioblastoma via Inducing xCT / GPX4 ‐Regulated Ferroptosis
Annals of Clinical and Translational Neurology · 2026
DOI: 10.1002/acn3.70173 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Peng Tao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, People's Republic of China. Hauptthemen laut MEDLINE: Ferroptosis, Glioblastoma, Amino Acid Transport System y+, Brain Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Natural Science Foundation of China, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Purpose
This study investigates NR4A1's paradoxical roles in glioblastoma (GBM) progression, focusing on its mechanistic link to ferroptosis regulation. We aimed to resolve conflicting reports of NR4A1 as both an oncogene and a tumor suppressor by defining its transcriptional control over xCT/GPX4‐mediated iron homeostasis and its clinical relevance in glioma survival.
Methods
TCGA cohort analysis ( n = 163) correlated NR4A1 expression with survival endpoints (OS/PFI/DSS, log‐rank p < 0.05). Functional validation employed U87/U251 GBM models for viability (CCK‐8), proliferation (EdU/colony formation), and migration assays (Transwell/wound healing). RNA sequencing (DESeq2, FDR < 0.05) and ChIP‐qPCR identified NR4A1‐xCT transcriptional regulation. Ferroptosis was quantified via lipid peroxidation (MDA/GSH/Fe 2+ ELISA, C11 BODIPY), while Western blotting mapped the NR4A1/xCT/GPX4/P53 axis. Orthotopic xenografts ( n = 6/group) evaluated therapeutic efficacy using biweekly tumor volumetry. All data were analyzed in triplicate (GraphPad Prism 8.0; t ‐test/ANOVA, * p < 0.05).
Conclusion
NR4A1 drives GBM progression by transcriptionally activating xCT/GPX4 to suppress ferroptosis. Dual targeting of NR4A1 and ferroptosis pathways synergistically inhibits tumor growth (64% reduction vs. controls, p = 0.008), providing a mechanistic rationale for overcoming therapy resistance in GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, People's Republic of China.
- Department of Neurology, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, People's Republic of China.
- Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, People's Republic of China.
- Department of Neurosurgery, Jingchu University of Technology Affiliated Jingmen People's Hospital, Jingmen, People's Republic of China.
ORCID-Profile: Qianxue Chen
Förderung
- the National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province
Zitieren
APA
Tao, P., Din, S., Fu, Z., Sun, Q., Zhu, X., Wei, Y., Qu, H., Zhang, X., Liu, J., Fu, C., & Chen, Q. (2026). NR4A1 Exerts Pro‐Tumor Role in Glioblastoma via Inducing xCT / GPX4 ‐Regulated Ferroptosis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70173
Vancouver
Tao P, Din S, Fu Z, Sun Q, Zhu X, Wei Y, et al. NR4A1 Exerts Pro‐Tumor Role in Glioblastoma via Inducing xCT / GPX4 ‐Regulated Ferroptosis. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70173
BibTeX
@article{Tao2026,
author = {Tao, Peng and Din, Shikuan and Fu, Zhengkang and Sun, Qian and Zhu, Xiwei and Wei, Yuxin and Qu, Huan and Zhang, Xinyi and Liu, Jiaxuan and Fu, Chuhua and Chen, Qianxue},
title = {NR4A1 Exerts Pro‐Tumor Role in Glioblastoma via Inducing xCT / GPX4 ‐Regulated Ferroptosis},
journal = {Annals of Clinical and Translational Neurology},
year = {2026},
doi = {10.1002/acn3.70173}
}
EUVIMED